Valuation VYNE Therapeutics Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-16 pm EST			5-day change	1st Jan Change
2.580 ^USD	-6.52%		-34.18%	-22.99%

Jan. 06	VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo	CI
Dec. 23	VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	265.2	54.59	8.705	32.52	38.06	38.06	-
Change	-	-79.42%	-84.05%	273.57%	17.03%	0%	-
Enterprise Value (EV)	265.2	54.59	8.705	32.52	38.06	38.06	38.06
Change	-	-79.42%	-84.05%	273.57%	17.03%	0%	0%
P/E ratio	-0.8x	-0.72x	-0.37x	-0.84x	-2.69x	-2.28x	-2.22x
PBR	-	-	-	-	-	-	-
PEG	-	0x	0x	0x	0x	-0.1x	-0.84x
Capitalization / Revenue	12.6x	3.7x	18.3x	76.7x	69.2x	152x	127x
EV / Revenue	0x	0x	0x	0x	69.2x	152x	127x
EV / EBITDA	-	-	-	-0x	-0.84x	-0.7x	-0.61x
EV / EBIT	-0x	-0x	-0x	-0x	-0.85x	-0.69x	-0.62x
EV / FCF	-1.93x	-0.97x	-	-	-	-	-
FCF Yield	-0%	-0%	-	-	-	-	-
Dividend per Share ²	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-
EPS ²	-141.8	-25.56	-7.28	-2.78	-0.96	-1.13	-1.16
Distribution rate	-	-	-	-	-	-	-
Net sales ¹	20.99	14.76	0.477	0.424	0.55	0.25	0.3
EBITDA ¹	-	-	-	-29.26	-45.5	-54.4	-62
EBIT ¹	-252.5	-68.03	-34.3	-29.26	-44.85	-55.25	-61.55
Net income ¹	-255.6	-73.33	-23.21	-28.45	-40.45	-53.3	-61.35
Net Debt	-	-	-	-	-	-	-
Reference price ²	113.760	18.360	2.700	2.330	2.580	2.580	2.580
Nbr of stocks (in thousands)	2,332	2,973	3,224	13,957	14,751	14,751	-
Announcement Date	3/4/21	3/17/22	3/9/23	2/29/24	-	-	-

¹USD in Million²USD

Estimates

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E ratio	EV / Sales	EV / EBITDA	Yield	Capi. ($)
VYNE THERAPEUTICS INC.	-2.88x	-	-	-	40.71M
VERTEX PHARMACEUTICALS INCORPORATED	-263.95x	9.2x	114.41x	-.--%	109B
REGENERON PHARMACEUTICALS, INC.	18.24x	4.68x	11.57x	-.--%	75.68B
ARGENX SE	624.53x	17.42x	-632.25x	-.--%	39.89B
BIONTECH SE	-34.98x	5.11x	-10.98x	-.--%	27.25B
BEIGENE, LTD.	-37.09x	5.31x	-37.38x	-.--%	21.5B
WUXI APPTEC CO., LTD.	16.33x	3.6x	10.29x	+1.84%	20.77B
NEUROCRINE BIOSCIENCES, INC.	35.44x	5.39x	20.23x	-.--%	14.43B
SUMMIT THERAPEUTICS INC.	-59.25x	-	-	-	13.42B
GENMAB A/S	17.74x	3.64x	11.28x	-.--%	13.01B
Average	31.41x	6.79x	-64.11x	+0.23%	33.53B
Weighted average by Cap.	-11.96x	7.79x	-38.21x	+0.12%